Entrada Therapeutics, Inc.
TRDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $210,782 | $129,013 | $0 | $0 |
| % Growth | 63.4% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $210,782 | $129,013 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $125,306 | $99,884 | $66,609 | $35,926 |
| G&A Expenses | $38,465 | $32,291 | $30,639 | $15,201 |
| SG&A Expenses | $38,465 | $32,291 | $30,639 | $15,201 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $163,771 | $132,175 | $97,248 | $51,127 |
| Operating Income | $47,011 | -$3,162 | -$97,248 | -$51,127 |
| % Margin | 22.3% | -2.5% | – | – |
| Other Income/Exp. Net | $19,474 | $15,218 | $2,632 | -$31 |
| Pre-Tax Income | $66,485 | $12,056 | -$94,616 | -$51,158 |
| Tax Expense | $859 | $18,741 | $0 | $0 |
| Net Income | $65,626 | -$6,685 | -$94,616 | -$51,158 |
| % Margin | 31.1% | -5.2% | – | – |
| EPS | 1.76 | -0.2 | -2.79 | -1.6 |
| % Growth | 980% | 92.8% | -74.4% | – |
| EPS Diluted | 1.68 | -0.2 | -2.79 | -1.6 |
| Weighted Avg Shares Out | 37,306 | 33,050 | 31,293 | 31,224 |
| Weighted Avg Shares Out Dil | 39,003 | 33,050 | 31,293 | 31,224 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,474 | $15,218 | $2,632 | $0 |
| Interest Expense | $0 | $0 | $2,632 | $0 |
| Depreciation & Amortization | $3,773 | $2,841 | $1,895 | $1,117 |
| EBITDA | $50,784 | -$321 | -$95,353 | -$50,010 |
| % Margin | 24.1% | -0.2% | – | – |